Discovery of [1,2,4]triazolo[1,5-a]pyrimidine-Imatinib Hybrids With Selective Cytotoxic Activity: A Mechanistically Divergent Series From Direct BCR-ABL1 Inhibition
Novel hybrid compounds targeting leukemia cells offer a fresh chemical scaffold worth exploring in drug discovery pipelines.
Six novel imatinib-triazolopyrimidine hybrid compounds were synthesized and evaluated in BCR-ABL1-positive CML cells; compound 2a showed cytotoxic activity through an ABL1-independent mechanism, establishing a structurally distinct scaffold with potential as an antimyeloproliferative lead. This is early-stage medicinal chemistry with a long translational path.
What the study was
- Study design
- Medicinal chemistry / drug discovery (in vitro)
- Population
- CML cell lines (K562 BCR-ABL1+)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- ChemMedChem
Why it surfaced
Novel scaffold addressing CML resistance; early drug discovery stage; in vitro only; off-target mechanism unclear but potentially interesting.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.